Cargando…
Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of t...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619667/ https://www.ncbi.nlm.nih.gov/pubmed/37920464 http://dx.doi.org/10.3389/fimmu.2023.1163159 |
_version_ | 1785130035761381376 |
---|---|
author | Abdelnabi, Rana Pérez, Patricia Astorgano, David Albericio, Guillermo Kerstens, Winnie Thibaut, Hendrik Jan Coelmont, Lotte Weynand, Birgit Labiod, Nuria Delgado, Rafael Montenegro, Dolores Puentes, Eugenia Rodríguez, Esteban Neyts, Johan Dallmeier, Kai Esteban, Mariano García-Arriaza, Juan |
author_facet | Abdelnabi, Rana Pérez, Patricia Astorgano, David Albericio, Guillermo Kerstens, Winnie Thibaut, Hendrik Jan Coelmont, Lotte Weynand, Birgit Labiod, Nuria Delgado, Rafael Montenegro, Dolores Puentes, Eugenia Rodríguez, Esteban Neyts, Johan Dallmeier, Kai Esteban, Mariano García-Arriaza, Juan |
author_sort | Abdelnabi, Rana |
collection | PubMed |
description | The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA–S(3P)]. Hamsters vaccinated with one or two doses of MVA-S(3P) developed high titers of S-binding IgG antibodies and neutralizing antibodies against the ancestral Wuhan SARS-CoV-2 virus and VoC beta, gamma, and delta, as well as against omicron, although with a somewhat lower neutralization activity. After SARS-CoV-2 challenge, vaccinated hamsters did not lose body weight as compared to matched placebo (MVA-WT) controls. Consistently, vaccinated hamsters exhibited significantly reduced viral RNA in the lungs and nasal washes, and no infectious virus was detected in the lungs in comparison to controls. Furthermore, almost no lung histopathology was detected in MVA-S(3P)-vaccinated hamsters, which also showed significantly reduced levels of proinflammatory cytokines in the lungs compared to unvaccinated hamsters. These results reinforce the use of MVA-S(3P) as a vaccine candidate against COVID-19 in clinical trials. |
format | Online Article Text |
id | pubmed-10619667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106196672023-11-02 Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters Abdelnabi, Rana Pérez, Patricia Astorgano, David Albericio, Guillermo Kerstens, Winnie Thibaut, Hendrik Jan Coelmont, Lotte Weynand, Birgit Labiod, Nuria Delgado, Rafael Montenegro, Dolores Puentes, Eugenia Rodríguez, Esteban Neyts, Johan Dallmeier, Kai Esteban, Mariano García-Arriaza, Juan Front Immunol Immunology The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA–S(3P)]. Hamsters vaccinated with one or two doses of MVA-S(3P) developed high titers of S-binding IgG antibodies and neutralizing antibodies against the ancestral Wuhan SARS-CoV-2 virus and VoC beta, gamma, and delta, as well as against omicron, although with a somewhat lower neutralization activity. After SARS-CoV-2 challenge, vaccinated hamsters did not lose body weight as compared to matched placebo (MVA-WT) controls. Consistently, vaccinated hamsters exhibited significantly reduced viral RNA in the lungs and nasal washes, and no infectious virus was detected in the lungs in comparison to controls. Furthermore, almost no lung histopathology was detected in MVA-S(3P)-vaccinated hamsters, which also showed significantly reduced levels of proinflammatory cytokines in the lungs compared to unvaccinated hamsters. These results reinforce the use of MVA-S(3P) as a vaccine candidate against COVID-19 in clinical trials. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10619667/ /pubmed/37920464 http://dx.doi.org/10.3389/fimmu.2023.1163159 Text en Copyright © 2023 Abdelnabi, Pérez, Astorgano, Albericio, Kerstens, Thibaut, Coelmont, Weynand, Labiod, Delgado, Montenegro, Puentes, Rodríguez, Neyts, Dallmeier, Esteban and García-Arriaza https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Abdelnabi, Rana Pérez, Patricia Astorgano, David Albericio, Guillermo Kerstens, Winnie Thibaut, Hendrik Jan Coelmont, Lotte Weynand, Birgit Labiod, Nuria Delgado, Rafael Montenegro, Dolores Puentes, Eugenia Rodríguez, Esteban Neyts, Johan Dallmeier, Kai Esteban, Mariano García-Arriaza, Juan Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters |
title | Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters |
title_full | Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters |
title_fullStr | Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters |
title_full_unstemmed | Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters |
title_short | Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters |
title_sort | optimized vaccine candidate mva-s(3p) fully protects against sars-cov-2 infection in hamsters |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619667/ https://www.ncbi.nlm.nih.gov/pubmed/37920464 http://dx.doi.org/10.3389/fimmu.2023.1163159 |
work_keys_str_mv | AT abdelnabirana optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT perezpatricia optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT astorganodavid optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT albericioguillermo optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT kerstenswinnie optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT thibauthendrikjan optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT coelmontlotte optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT weynandbirgit optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT labiodnuria optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT delgadorafael optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT montenegrodolores optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT puenteseugenia optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT rodriguezesteban optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT neytsjohan optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT dallmeierkai optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT estebanmariano optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters AT garciaarriazajuan optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters |